Veritas Pharma Increases Investment in Cannevert

October 11, 2016, Vancouver, B.C. – Veritas Pharma Inc. (“VRT” or the “Company”) (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is pleased to announce that Veritas has completed advancing $750,000 to Cannevert Therapeutics Ltd. With this payment the Company has made 50%...

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!